The Multifaceted Role of Neutrophils in NSCLC in the Era of Immune Checkpoint Inhibitors
Cancers · 10.07.2024 · 16 (14) · 2507
DOI: 10.3390/cancers16142507 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 10.07.2024. Verfasst von Shucheng Miao und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Head & Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CPRIT, CCSG, NIH HHS.
Abstract (Originalsprache)
Lung cancer is the most common cause of cancer-related death in both males and females in the U.S. and non-small-cell lung cancer (NSCLC) accounts for 85%. Although the use of first- or second-line immune checkpoint inhibitors (ICIs) exhibits remarkable clinical benefits, resistance to ICIs develops over time and dampens the efficacy of ICIs in patients. Tumor-associated neutrophils (TANs) have an important role in modulating the tumor microenvironment (TME) and tumor immune response. The major challenge in the field is to characterize the TANs in NSCLC TME and understand the link between TAN-related immunosuppression with ICI treatment response. In this review, we summarize the current studies of neutrophil interaction with malignant cells, T-cells, and other components in the TME. Ongoing clinical trials are aimed at utilizing reagents that have putative effects on tumor-associated neutrophils, in combination with ICI. Elevated neutrophil populations and neutrophil-associated factors could be potential therapeutic targets to enhance anti-PD1 treatment in NSCLC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Head & Neck Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA.
- The University of Texas MD Anderson Cancer Center, UTHealth at Houston Graduate School of Biomedical Sciences, Houston, TX 77030, USA.
ORCID-Profile: Shucheng Miao
Förderung
- CPRIT
- CCSG
- NIH HHS
- NIH
- Rexanna’s Foundation for Fighting Lung Cancer
- University of Texas MD Anderson Lung Cancer Moon Shots Program
Zitieren
APA
Miao, S., Rodriguez, B. L., & Gibbons, D. L. (2024). The Multifaceted Role of Neutrophils in NSCLC in the Era of Immune Checkpoint Inhibitors. Cancers, 16(14), 2507. https://doi.org/10.3390/cancers16142507
Vancouver
Miao S, Rodriguez BL, Gibbons DL. The Multifaceted Role of Neutrophils in NSCLC in the Era of Immune Checkpoint Inhibitors. Cancers. 2024;16(14):2507. doi:10.3390/cancers16142507
BibTeX
@article{Miao2024,
author = {Miao, Shucheng and Rodriguez, Bertha Leticia and Gibbons, Don L},
title = {The Multifaceted Role of Neutrophils in NSCLC in the Era of Immune Checkpoint Inhibitors},
journal = {Cancers},
year = {2024},
volume = {16},
number = {14},
pages = {2507},
doi = {10.3390/cancers16142507}
}
EUVIMED